Specialty drugs made up 70% of an increase in pharmaceutical spending last year, while diabetes was the No. 1 therapeutic category, contributing 16.1%, according to the 2011 Medco Drug Trend Report. Biosimilar drugs, which are expected to be created over the next 10 years, will help control costs of specialty drugs and result in about $340 billion in savings if drugmakers exhibit interchangeability, said Medco Chairman and CEO David Snow.

Related Summaries